Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2

Status

Completed 3Recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Myeloid 4Classical hematology 2

Conditions

Colorectal Neoplasms 24Neoplasms 12Colonic Neoplasms 12Breast Neoplasms 12Prostatic Neoplasms 9Polycythemia Vera 9Venous Thromboembolism 8Multiple Myeloma 8Recurrence 5Rectal Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Thrombocythemia, Essential 4Ovarian Neoplasms 4Neoplasms, Plasma Cell 4Neoplasm Metastasis 4Myeloproliferative Disorders 4Barrett Esophagus 4Precancerous Conditions 3Melanoma 3Esophageal Neoplasms 3Adenomatous Polyps 3Adenoma 3Tobacco Use Disorder 2Thrombosis 2Thromboembolism 2Smoking Cessation 2Sarcoma 2Primary Myelofibrosis 2Neoplastic Cells, Circulating 2Neoplasms by Site 2

Interventions

fludarabine phosphate 25Cyclophosphamide 24Peripheral Blood Stem Cell Transplantation 23Busulfan 17Tacrolimus 15Methotrexate 13Cyclosporine 13ruxolitinib 12Whole-Body Irradiation 12Mycophenolic Acid 12Antilymphocyte Serum 11Filgrastim 8Decitabine 7fludarabine 6Etoposide 611-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 6peginterferon alfa-2a 5Radiotherapy 5Methylprednisolone 5Cytarabine 5Carboplatin 5Prednisone 4Melphalan 4Biopsy 4Aspirin 4givinostat hydrochloride 3givinostat 3bomedemstat 3anagrelide 3Topotecan 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Thrombocythemia, Essential × Aspirin × Clear all
NCT05198960 2026-03-20

AVAJAK

University Hospital, Brest

Phase 3 Recruiting
1,308 enrolled
Classical hematologyMyeloid

Hemorrhage, Polycythemia Vera, Thrombocythemia, Essential, Venous Thromboembolism, Primary Myelofibrosis

NCT04243122 2024-05-29

AIRPORT-MPN

Ottawa Hospital Research Institute

Phase 2 Completed
44 enrolled
Classical hematologyMyeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Venous Thromboembolism, Primary Myelofibrosis

NCT01259856 2019-04-30

Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)

Icahn School of Medicine at Mount Sinai

Phase 3 Completed
168 enrolled 16 charts
Myeloid

Polycythemia Vera, Thrombocythemia, Essential

NCT01259817 2017-01-11

Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)

Icahn School of Medicine at Mount Sinai

Phase 2 Completed
135 enrolled
Myeloid

Polycythemia Vera, Thrombocythemia, Essential

Data powered by HemOnc (CC BY 4.0) Colophon âš¡